{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:29:59Z","timestamp":1788881399710,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003107","name":"bundesministerium f\u00fcr gesundheit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>COVID-19, the pandemic disease caused by infection with SARS-CoV-2, may take highly variable clinical courses, ranging from symptom-free and pauci-symptomatic to fatal disease. The goal of the current study was to assess the association of COVID-19 clinical courses controlled by patients\u2019 adaptive immune responses without progression to severe disease with patients\u2019 Human Leukocyte Antigen (HLA) genetics, AB0 blood group antigens, and the presence or absence of near-loss-of-function delta 32 deletion mutant of the C\u2013C chemokine receptor type 5 (CCR5).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patient and methods<\/jats:title>\n                <jats:p>An exploratory observational study including 157 adult COVID-19 convalescent patients was performed with a median follow-up of 250\u00a0days. The impact of different HLA genotypes, AB0 blood group antigens, and the CCR5 mutant CD195 were investigated for their role in the clinical course of COVID-19. In addition, this study addressed levels of severity and morbidity of COVID-19. The association of the immunogenetic background parameters were further related to patients\u2019 humoral antiviral immune response patterns by longitudinal observation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Univariate HLA analyses identified putatively protective HLA alleles (HLA class II DRB1*01:01 and HLA class I B*35:01, with a trend for DRB1*03:01). They were associated with reduced durations of disease instead decreased (rather than increased) total anti-S IgG levels. They had a higher virus neutralizing capacity compared to non-carriers. Conversely, analyses also identified HLA alleles (HLA class II DQB1*03:02 und HLA class I B*15:01) not associated with such benefit in the patient cohort of this study. Hierarchical testing by Cox regression analyses confirmed the significance of the protective effect of the HLA alleles identified (when assessed in composite) in terms of disease duration, whereas AB0 blood group antigen heterozygosity was found to be significantly associated with disease severity (rather than duration) in our cohort. A suggestive association of a heterozygous CCR5 delta 32 mutation status with prolonged disease duration was implied by univariate analyses but could not be confirmed by hierarchical multivariate testing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The current study shows that the presence of HLA class II DRB1*01:01 and HLA class I B*35:01 is of even stronger association with reduced\u00a0disease duration in mild and moderate COVID-19 than age or any other potential risk factor assessed. Prospective studies in larger patient populations also including novel SARS-CoV-2 variants will be required to assess the impact of HLA genetics on the capacity of mounting protective vaccination responses in the future.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-021-00560-4","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T12:03:04Z","timestamp":1631793784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19"],"prefix":"10.1186","volume":"26","author":[{"given":"Johannes C.","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht G.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9112-1024","authenticated-orcid":false,"given":"Edwin","family":"B\u00f6lke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Uhrberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Keitel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Feldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"H\u00e4ussinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ortwin","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Marion","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Balz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Enczmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Rox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derik","family":"Hermsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Schulze-Bosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Kindgen-Milles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram Trudo","family":"Knoefel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"van Griensven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Haussmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balint","family":"Tamaskovics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Plettenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Scheckenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Pedoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitti","family":"Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Grebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Ehrhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Peiper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina Alexandra","family":"Buhren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Calles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"St\u00f6hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Lichtenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi F.","family":"Freise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Lutterbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Rezazadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Budach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Matuschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"560_CR1","doi-asserted-by":"publisher","first-page":"198040","DOI":"10.1016\/j.virusres.2020.198040","volume":"286","author":"JH Ellwanger","year":"2020","unstructured":"Ellwanger JH, Kulmann-Leal B, Kaminski VL, Rodrigues AG, Bragatte MAS, Chies JAB. Beyond HIV infection: neglected and varied impacts of CCR5 and CCR5\u039432 on viral diseases. Virus Res. 2020;286:198040.","journal-title":"Virus Res"},{"key":"560_CR2","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1086\/524709","volume":"197","author":"E Kindberg","year":"2008","unstructured":"Kindberg E, Mickiene A, Ax C, et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis. 2008;197:266\u20139.","journal-title":"J Infect Dis"},{"key":"560_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1086\/524691","volume":"197","author":"JK Lim","year":"2008","unstructured":"Lim JK, Louie CY, Glaser C, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis. 2008;197:262\u20135.","journal-title":"J Infect Dis"},{"key":"560_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.cca.2020.07.012","volume":"510","author":"AK Panda","year":"2020","unstructured":"Panda AK, Padhi A, Prusty BAK. CCR5 Delta32 minorallele is associated with susceptibility to SARS-CoV-2 infection and death: An epidemiological investigation. Clin Chim Acta. 2020;510:60\u20131.","journal-title":"Clin Chim Acta"},{"key":"560_CR5","doi-asserted-by":"publisher","first-page":"e104749","DOI":"10.15252\/embj.2020104749","volume":"39","author":"A Mart\u00edn-Leal","year":"2020","unstructured":"Mart\u00edn-Leal A, Blanco R, Casas J, et al. CCR5 deficiency impairs CD4(+) T-cell memory responses and antigenic sensitivity through increased ceramide synthesis. EMBO J. 2020;39:e104749.","journal-title":"EMBO J"},{"key":"560_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41423-020-0473-0","volume":"17","author":"G Rijkers","year":"2020","unstructured":"Rijkers G, Vervenne T, van der Pol P. More bricks in the wall against SARS-CoV-2 infection: involvement of gamma9delta2 T cells. Cell Mol Immunol. 2020;17:771\u20132.","journal-title":"Cell Mol Immunol"},{"key":"560_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","volume":"17","author":"M Zheng","year":"2020","unstructured":"Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17:533\u20135.","journal-title":"Cell Mol Immunol"},{"key":"560_CR8","first-page":"687","volume":"5","author":"CD Pauza","year":"2014","unstructured":"Pauza CD, Poonia B, Li H, Cairo C, Chaudhry S. Gammadelta T cells in HIV disease: past, present, and future. Front Immunol. 2014;5:687.","journal-title":"Front Immunol"},{"issue":"16","key":"560_CR9","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1056\/NEJMoa2020283","volume":"383","author":"D Ellinghaus","year":"2020","unstructured":"Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide association study of severe covid-19 with respiratory failure. N Engl J Med. 2020;383(16):1522\u201334.","journal-title":"N Engl J Med"},{"key":"560_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","volume":"22","author":"A Nelde","year":"2021","unstructured":"Nelde A, Bilich T, Heitmann JS, et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol. 2021;22:74\u201385.","journal-title":"Nat Immunol"},{"key":"560_CR11","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12967-020-02515-5","volume":"18","author":"S Pisanti","year":"2020","unstructured":"Pisanti S, Deelen J, Gallina AM, et al. Correlation of the two most frequent HLA haplotypes in the Italian population to the differential regional incidence of Covid-19. J Transl Med. 2020;18:352.","journal-title":"J Transl Med"},{"key":"560_CR12","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s10038-020-0808-9","volume":"65","author":"Y Toyoshima","year":"2020","unstructured":"Toyoshima Y, Nemoto K, Matsumoto S, Nakamura Y, Kiyotani K. SARS-CoV-2 genomic variations associated with mortality rate of COVID-19. J Hum Genet. 2020;65:1075\u201382.","journal-title":"J Hum Genet"},{"key":"560_CR13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1086\/421523","volume":"190","author":"MH Ng","year":"2004","unstructured":"Ng MH, Lau KM, Li L, et al. Association of human-leukocyte-antigen class I (B*0703) and class II (DRB1*0301) genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome. J Infect Dis. 2004;190:515\u20138.","journal-title":"J Infect Dis"},{"key":"560_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1128\/JCM.44.2.359-365.2006","volume":"44","author":"Y-MA Chen","year":"2006","unstructured":"Chen Y-MA, Liang S-Y, Shih Y-P, et al. Epidemiological and genetic correlates of severe acute respiratory syndrome coronavirus infection in the hospital with the highest nosocomial infection rate in Taiwan in 2003. J Clin Microbiol. 2006;44:359\u201365.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"560_CR15","first-page":"89","volume":"19","author":"D Golinelli","year":"2020","unstructured":"Golinelli D. On the association between the ABO blood group and COVID-19 susceptibility. Blood Transfus. 2020;19(1):89\u201390.","journal-title":"Blood Transfus"},{"key":"560_CR16","doi-asserted-by":"publisher","first-page":"5761","DOI":"10.1038\/s41467-020-19623-x","volume":"11","author":"M Zietz","year":"2020","unstructured":"Zietz M, Zucker J, Tatonetti NP. Associations between blood type and COVID-19 infection, intubation, and death. Nat Commun. 2020;11:5761.","journal-title":"Nat Commun"},{"key":"560_CR17","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1182\/bloodadvances.2020002623","volume":"4","author":"RL Hoiland","year":"2020","unstructured":"Hoiland RL, Fergusson NA, Mitra AR, et al. The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19. Blood Adv. 2020;4:4981\u20139.","journal-title":"Blood Adv"},{"key":"560_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/tan.13384","volume":"92","author":"V Balz","year":"2018","unstructured":"Balz V, Fischer J, Krause S, Enczmann J. A novel HLA-B variant, HLA-B*14:02:16, discovered by amplicon-based next-generation sequencing. Hla. 2018;92:323\u20134.","journal-title":"Hla"},{"issue":"3","key":"560_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/tan.13207","volume":"91","author":"V Balz","year":"2018","unstructured":"Balz V, Krause S, Fischer J, Enczmann J. More than 150 novel variants of HLA class I genes detected in German Stem Cell Donor Registry and UCLA International Cell Exchange samples. HLA. 2018;91(3):187\u201394. https:\/\/doi.org\/10.1111\/tan.13207.","journal-title":"HLA"},{"key":"560_CR20","doi-asserted-by":"publisher","first-page":"114025","DOI":"10.1016\/j.jviromet.2020.114025","volume":"288","author":"J Mari\u00ebn","year":"2020","unstructured":"Mari\u00ebn J, Ceulemans A, Michiels J, et al. Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay. J Virol Methods. 2020;288:114025.","journal-title":"J Virol Methods"},{"key":"560_CR21","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","volume":"5","author":"J Seow","year":"2020","unstructured":"Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5:1598\u2013607.","journal-title":"Nat Microbiol"},{"key":"560_CR22","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1172\/JCI142004","volume":"130","author":"SL Klein","year":"2020","unstructured":"Klein SL, Pekosz A, Park HS, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest. 2020;130:6141\u201350.","journal-title":"J Clin Invest"},{"key":"560_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciimmunol.abe0367","volume":"5","author":"AS Iyer","year":"2020","unstructured":"Iyer AS, Jones FK, Nodoushani A, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020;5:1.","journal-title":"Sci Immunol"},{"key":"560_CR24","doi-asserted-by":"publisher","first-page":"100036","DOI":"10.1016\/j.xcrm.2020.100036","volume":"1","author":"M Yarmarkovich","year":"2020","unstructured":"Yarmarkovich M, Warrington JM, Farrel A, Maris JM. Identification of SARS-CoV-2 vaccine epitopes predicted to induce long-term population-scale immunity. Cell Rep Med. 2020;1:100036.","journal-title":"Cell Rep Med"},{"key":"560_CR25","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/glycob\/cwn093","volume":"18","author":"P Guillon","year":"2008","unstructured":"Guillon P, Cl\u00e9ment M, S\u00e9bille V, et al. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology. 2008;18:1085\u201393.","journal-title":"Glycobiology"},{"key":"560_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciimmunol.abd6832","volume":"5","author":"C Maucourant","year":"2020","unstructured":"Maucourant C, Filipovic I, Ponzetta A, et al. Natural killer cell immunotypes related to COVID-19 disease severity. Sci Immunol. 2020;5:1.","journal-title":"Sci Immunol"},{"key":"560_CR27","doi-asserted-by":"publisher","first-page":"605688","DOI":"10.3389\/fimmu.2020.605688","volume":"11","author":"R Littera","year":"2020","unstructured":"Littera R, Campagna M, Deidda S, et al. Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course The Sardinian Experience. Front Immunol. 2020;11:605688.","journal-title":"Front Immunol"},{"key":"560_CR28","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/tan.14047","volume":"96","author":"A Novelli","year":"2020","unstructured":"Novelli A, Andreani M, Biancolella M, et al. HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients. Hla. 2020;96:610\u20134.","journal-title":"Hla"},{"key":"560_CR29","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489-501.e15.","journal-title":"Cell"},{"key":"560_CR30","first-page":"66","volume":"1","author":"A Casadevall","year":"2020","unstructured":"Casadevall A, Grossman BJ, Henderson JP, et al. The assessment of convalescent plasma efficacy against COVID-19. Med (N Y). 2020;1:66\u201377.","journal-title":"Med (N Y)"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-021-00560-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-021-00560-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-021-00560-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T12:05:01Z","timestamp":1631793901000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-021-00560-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["560"],"URL":"https:\/\/doi.org\/10.1186\/s40001-021-00560-4","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"assertion":[{"value":"7 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local ethics board registration and approval number 2020-1116.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors gave consent for the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}